Last Updated on May 25, 2021 by The Health Master
Drug firm Bharat Parenterals on Saturday said it has received approval from the Drugs Controller General of India (DCGI) for favipiravir oral suspension, to be used for treatment of Covid-19 patients.
The company has received licence and authorisation from DCGI to manufacture and market favipiravir oral suspension l00mg/ml, Bharat Parenterals said in a regulatory filing.
Favipiravir, an antiviral drug, was approved in Japan in 2014 for the treatment of novel or re-emerging influenza virus infections.
Also read:
Natco Pharma gets USFDA nod for Lenalidomide capsules
Unichem Labs gets USFDA approval for Amitriptyline HCL Tablets
Alembic gets USFDA Final nod for Lurasidone HCL Tablets
Alembic gets USFDA nod for depression treatment drug
Caplin gets USFDA nod for Neostigmine Methylsulfate Injection
Gilead gets USFDA nod to treat metastatic urothelial cancer
Also read:
Latest Notifications: Hospital – RMI (Recognized Medical Institution)
DTAB dismisses proposal for indication of Green, Red, Brown dot on…
DRDO develops C-19 Antibody detection kit
Website launched to track Oxygen availability across India
Natco Pharma gets USFDA nod for Lenalidomide capsules
PCI begins approval process for academic year 2021-2022 for Pharmacy institutions
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
